Alnylam Pharmaceuticals, Inc.
Coronavirus iRNA compositions and methods of use thereof

Last updated:

Abstract:

The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the coronavirus genome. The invention also relates to methods of using such RNAi agents to inhibit expression of a coronavirus genome and to methods of treating or preventing a coronavirus-associated disease in a subject.

Status:
Grant
Type:

Utility

Filling date:

17 May 2021

Issue date:

28 Dec 2021